Sign in
ATTO Stock Price, Chart, Stats & News
Attovia Therapeutics, Inc.
Save
Attovia Therapeutics, Inc. (ATTO) does not currently pay a dividend.
895.02M
Market cap
–
Current P/E
–
Forward P/E
ATTO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.53% |
Operating margin | 5.00% |
Pretax margin | -5.82% |
Net margin | -6.22% |
Effective tax rate | -6.87% |
ROA | -8.18% |
ROE | -165.66% |
D/E | -70.47x |
Interest coverage ratio | 0.79x |
ATTO valuation
P/E | – |
P/S | 0.00x |
P/B | -0.65x |
P/CF | 0.16x |
P/FCF | -1.18x |
P/OCF | 0.16x |
PEG | -0.00x |
EV multiple | -2.50x |
About
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Similar securities
Based on sector and market capitalization
Report issue